Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
We report the results of HLA-matched unrelated donor allogeneic stem cell transplantation with new GVHD prophylaxis regimen consisted of cyclosporine, methotrexate and low-dose mycophenolate mofetil in 139 patients with hematologic malignancies. The incidence of grades II-IV and III-IV acute GVHD were 43.0% and 17.3%, respectively. The incidence of chronic GVHD was 42.1%, with 16.5% extensive grade. The cumulative incidence of transplant-related mortality at 100 days and 3 years were 7.9% and 29.7%, respectively. Three-year overall survival, disease-free survival and relapse incidence were 58.7%, 55.3% and 19.6%, respectively. These results suggest the new regime may be effective for the prophylaxis of acute and chronic GVHD in unrelated donor transplantation.
['Zhu|Xiaoli|X|', 'Lai|Xiaoyu|X|', 'Luo|Yi|Y|', 'Shi|Jimin|J|', 'Tan|Yamin|Y|', 'Zheng|Weiyan|W|', 'He|Jingsong|J|', 'Xie|Wanzhuo|W|', 'Li|Li|L|', 'Zhang|Jie|J|', 'Ye|Xiujin|X|', 'Lin|Maofang|M|', 'Cai|Zhen|Z|', 'Huang|He|H|']
D000293:Adolescent D000328:Adult D002648:Child D016572:Cyclosporine D004305:Dose-Response Relationship, Drug D004359:Drug Therapy, Combination D005260:Female D005500:Follow-Up Studies D006084:Graft Rejection D006085:Graft Survival D006086:Graft vs Host Disease D019337:Hematologic Neoplasms D018380:Hematopoietic Stem Cell Transplantation D006650:Histocompatibility Testing D006801:Humans D007166:Immunosuppressive Agents D008297:Male D008727:Methotrexate D008875:Middle Aged D009017:Morbidity D009173:Mycophenolic Acid D009364:Neoplasm Recurrence, Local D011379:Prognosis D015996:Survival Rate D014184:Transplantation, Homologous D061349:Unrelated Donors D055815:Young Adult
Mycophenolate mofetil GVHD Unrelated donor Allogeneic stem cell transplantation